Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Latest News
    • Lutikizumab does not...

    Lutikizumab does not significantly improve pain or imaging outcomes in hand osteoarthritis

    Written by Medha Baranwal Baranwal Published On 2019-06-23T19:10:21+05:30  |  Updated On 23 Jun 2019 7:10 PM IST
    Lutikizumab does not significantly improve pain or imaging outcomes in hand osteoarthritis

    DELHI: Interleukin-1α (IL-1α) and IL-1β are potential mediators of synovitis, cartilage damage, and bone loss in patients with erosive hand osteoarthritis (HOA). Lutikizumab is an immunoglobulin that binds and adequately blocks both IL-1α and IL-1β. Now, a recent study has found that despite adequate neutralization of IL-1α and IL-1β, treatment with lutikizumab, versus placebo, did not result in significantly better improvements in hand joint pain or imaging outcomes in hand osteoarthritis.



    Results of a phase 2a, randomised, double-blind study, published in the BMJ Journal Annals of the Rheumatic Diseases, found that treatment with lutikizumab resulted in more frequent injection site reactions, neutropenia, and discontinuations compared to placebo.

    Hand osteoarthritis is a common musculoskeletal disease, with prevalence rising steeply with increasing age. The disease is associated with hand pain, stiffness, functional limitation, decreased grip strength and reduced quality of life.


    Margreet Kloppenburg, Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, and colleagues conducted the study to assess the safety and efficacy of Lutikizumab for the treatment of erosive hand osteoarthritis.


    “Despite adequate systemic lutikizumab pharmacodynamic effects, lutikizumab did not significantly improve clinical outcomes or imaging outcomes in patients with erosive hand osteoarthritis, compared to placebo,” said Dr Kloppenburg, “suggesting that targeting IL-1 may be ineffective for the treatment of erosive hand osteoarthritis.”


    For the study, the researchers randomized 132 study participants to receive either 200 mg of lutikizumab subcutaneously every two weeks for 24 weeks or a placebo. Blood samples were taken at baseline and 26 weeks to determine lutikizumab levels and anti-drug antibody responses to the medication.

    The primary endpoint was a change in Australian/Canadian Osteoarthritis Hand Index (AUSCAN) pain subdomain score from baseline to 16 weeks.


    Also Read: Avoid DMARDs in hand osteoarthritis patients, recommends Updated EULAR guidelines

    Key findings of the study include:




    • Of 132 randomised subjects, 1 received no study drug and 110 completed the study (placebo, 61/67 (91%); lutikizumab, 49/64 (77%)).

    • Based on the blood analysis, patients receiving lutikizumab experienced significant reductions in serum IL-1alpha and IL-1beta levels, as well as significant drops in neutrophils, proteins indicating liver inflammation, markers of synovitis.

    • These patients also saw significant mean reductions in platelet counties, white blood cell counts, and alkaline phosphatase, as well as increases in high-density lipoprotein cholesterol.

    • Placebo patients did not see the same changes.

    • The number of tender and swollen joints at 26 weeks was similar between placebo and lutikizumab, as were other outcomes, including pain, stiffness, and grip strength.

    • Imaging also showed similar radiographic evidence of erosive joints between both groups.

    • Equivalent proportions of participants in both groups experienced adverse events, pointing to similar safety profiles, as well.

    • The lutikizumab and placebo groups saw similar amounts of rescue medication use.


    Also Read: Management of Hand Osteoarthritis : EULAR 2018 Recommendations

    " Targeting IL-1 may not be a good clinical option for treatment erosive hand osteoarthritis, suggested the authors.

    BMJ journalsbone losscartilage damageerosive hand osteoarthritisHANDhand joint painIL-1αIL-1βinterleukininterleukin 1βinterleukin-1αJoint painjointsLutikizumabosteoarthritisPainrescue medicationswollen jointssynovitistreatment

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok